Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.

Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.

Abstract: A method for treating snoring, sleep apnoea and other forms of sleep disordered breathing involves administration to a patient of a therapeutically effective amount of topiramate over an appropriate period of time, such as a period substantially coinciding with the sleep period of a patient. A useful route of administration is per os. Also disclosed is the use of topiramate for the diagnosis of snoring, sleep apnoea and other forms of sleep disordered breathing.

Abstract: The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.

Abstract: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.

Abstract: A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier.

Abstract: The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day.

Abstract: A method and apparatus for detecting breathing disorders and controlling a breathing ventilator using an artificial neural network working on signals indicative of a patient's physiological status. Preferably the artificial neural network works on a signal indicative of the pressure or flow of supplied breathing gas divided into two or more intervals (401, 402, 403, 404) indicative of patient (1) breathing cycle phases.

Abstract: A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament for treating or preventing snoring, OSA and/or CSA and of a diagnostic device, kit or composition; a protective patch comprising AcHT or CA; and a pharmaceutical composition comprising AcHT or CA and an agent capable of alleviating the effects of snoring OSA and/or CSA, in combined amounts effective in the treatment of snoring OSA and/or CSA, and a carrier.

Abstract: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.

Abstract: A method for treating snoring, sleep apnoea and other forms of sleep disordered breathing comprises administration to a patient of a therapeutically effective amount of topiramate over an appropriate period of time, such as a period substantially coniciding with the sleep period of a patient. A useful route of administration is per os. Also disclosed is the use of topiramate for the diagnosis of snoring, sleep apnoea and other forms of sleep disordered breathing.

Abstract: A method for identification of an infant being particularly susceptible to sudden infant death syndrome (SIDS) comprises the determination of an Helicobacter pylori infection in the infant's mother, particularly by detection of antibodies to H. pylori of the IgG type, in a blood sample drawn from the infant's mother or by determination of carbon dioxide formed from urea in the air exhaled from the infant's mother upon oral administration of a challenge dose of urea. Also disclosed is the use of an antibiotic effective against H. pylori for the manufacture of a medicament for administration to mothers and other persons infected by H. pylori and coming into close bodily contact with infants below two years of age, and a method of prevention of SIDS by administration of that antibiotic.

Abstract: This invention relates to a method for treating snoring, sleep apnea and other form of sleep-disordered breathing, which comprises administration of a therapeutically effective dose of an acetyl choline esterase inhibitor (CEI) such as pyridostigmine or a pharmaceutically acceptable salt thereof.